Alnylam Grants MWG Biotech License to Fundamental RNAi Patents for Applications in the Research Products Market
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has granted MWG Biotech AG a non-exclusive license to provide research products and services in RNA interference (RNAi) under the Kreutzer-Limmer patent family owned by Alnylam. This patent family covers short interfering RNAs (siRNAs) and their use to mediate RNAi in mammalian cells.
"This agreement with MWG, an international genomic solution provider, continues to highlight the value of the Alnylam-owned Kreutzer-Limmer patent family as a critical component of fundamental intellectual property in the field of RNAi," said Vincent Miles, Ph.D., Senior Vice President, Business Development of Alnylam Pharmaceuticals. "By leveraging our portfolio of leading IP, we are creating value today and for the future by amassing an increasing number of license agreements with leading reagent and service providers. To date, fourteen companies have taken licenses for therapeutic or research product applications, including eight research product suppliers."
"This license strengthens our siRNA offering and is part of our commitment to build a high quality presence in siRNA design and production," said Dr. Wolfgang Pieken, CEO of MWG Biotech AG.
Other news from the department business & finance
